Houston, Texas, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced that Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the H.C, Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.
Dr. Tyle will present on the topic titled “Novel Approaches to Tumor Eradication”. Invectys, Inc focuses on a multi-modality approach to targeting HLA-G on tumor cells and also an approach with universal tumor antigen telomerase. The presentation is virtual and will be available on demand for the duration of the conference.
If you would like to set up a meeting, feel free to contact us at contactus@invectys.com.
About Invectys
Invectys, Inc. is a clinical stage immuno-oncology company spun-out of the world renown Pasteur Institute, Paris. Invectys has two wholly owned subsidiaries, Invectys, S.A. (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is dedicated to the development of the CPRIT initiative. Since 2010, Invectys has raised over $58 million in private funds to develop two innovative platforms of immunotherapy products which target “universal” tumor antigens.
Contact:
Invectys, Inc. – Rosie Williams
contactus@invectys.com
